2025-02-012026-01-312026-01-31false15432020U-PLOID BIOTECHNOLOGIES LTD2026-04-2872110falseiso4217:GBPxbrli:pure154320202025-01-31154320202026-01-31154320202025-02-012026-01-31154320202024-01-21154320202025-01-31154320202024-01-222025-01-3115432020bus:SmallEntities2025-02-012026-01-3115432020bus:AuditExempt-NoAccountantsReport2025-02-012026-01-3115432020bus:FullAccounts2025-02-012026-01-3115432020bus:PrivateLimitedCompanyLtd2025-02-012026-01-3115432020core:WithinOneYear2026-01-3115432020core:AfterOneYear2026-01-3115432020core:WithinOneYear2025-01-3115432020core:AfterOneYear2025-01-3115432020core:ShareCapital2026-01-3115432020core:SharePremium2026-01-3115432020core:RevaluationReserve2026-01-3115432020core:OtherReservesSubtotal2026-01-3115432020core:RetainedEarningsAccumulatedLosses2026-01-3115432020core:ShareCapital2025-01-3115432020core:SharePremium2025-01-3115432020core:RevaluationReserve2025-01-3115432020core:OtherReservesSubtotal2025-01-3115432020core:RetainedEarningsAccumulatedLosses2025-01-3115432020core:LandBuildings2026-01-3115432020core:PlantMachinery2026-01-3115432020core:Vehicles2026-01-3115432020core:FurnitureFittings2026-01-3115432020core:OfficeEquipment2026-01-3115432020core:NetGoodwill2026-01-3115432020core:IntangibleAssetsOtherThanGoodwill2026-01-3115432020core:ListedExchangeTraded2026-01-3115432020core:UnlistedNon-exchangeTraded2026-01-3115432020core:LandBuildings2025-01-3115432020core:PlantMachinery2025-01-3115432020core:Vehicles2025-01-3115432020core:FurnitureFittings2025-01-3115432020core:OfficeEquipment2025-01-3115432020core:NetGoodwill2025-01-3115432020core:IntangibleAssetsOtherThanGoodwill2025-01-3115432020core:ListedExchangeTraded2025-01-3115432020core:UnlistedNon-exchangeTraded2025-01-3115432020core:LandBuildings2025-02-012026-01-3115432020core:PlantMachinery2025-02-012026-01-3115432020core:Vehicles2025-02-012026-01-3115432020core:FurnitureFittings2025-02-012026-01-3115432020core:OfficeEquipment2025-02-012026-01-3115432020core:NetGoodwill2025-02-012026-01-3115432020core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3115432020core:ListedExchangeTraded2025-02-012026-01-3115432020core:UnlistedNon-exchangeTraded2025-02-012026-01-3115432020core:MoreThanFiveYears2025-02-012026-01-3115432020core:Non-currentFinancialInstruments2026-01-3115432020core:Non-currentFinancialInstruments2025-01-3115432020dpl:CostSales2025-02-012026-01-3115432020dpl:DistributionCosts2025-02-012026-01-3115432020core:LandBuildings2025-02-012026-01-3115432020core:PlantMachinery2025-02-012026-01-3115432020core:Vehicles2025-02-012026-01-3115432020core:FurnitureFittings2025-02-012026-01-3115432020core:OfficeEquipment2025-02-012026-01-3115432020dpl:AdministrativeExpenses2025-02-012026-01-3115432020core:NetGoodwill2025-02-012026-01-3115432020core:IntangibleAssetsOtherThanGoodwill2025-02-012026-01-3115432020dpl:GroupUndertakings2025-02-012026-01-3115432020dpl:ParticipatingInterests2025-02-012026-01-3115432020dpl:GroupUndertakingscore:ListedExchangeTraded2025-02-012026-01-3115432020core:ListedExchangeTraded2025-02-012026-01-3115432020dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-02-012026-01-3115432020core:UnlistedNon-exchangeTraded2025-02-012026-01-3115432020dpl:CostSales2024-01-222025-01-3115432020dpl:DistributionCosts2024-01-222025-01-3115432020core:LandBuildings2024-01-222025-01-3115432020core:PlantMachinery2024-01-222025-01-3115432020core:Vehicles2024-01-222025-01-3115432020core:FurnitureFittings2024-01-222025-01-3115432020core:OfficeEquipment2024-01-222025-01-3115432020dpl:AdministrativeExpenses2024-01-222025-01-3115432020core:NetGoodwill2024-01-222025-01-3115432020core:IntangibleAssetsOtherThanGoodwill2024-01-222025-01-3115432020dpl:GroupUndertakings2024-01-222025-01-3115432020dpl:ParticipatingInterests2024-01-222025-01-3115432020dpl:GroupUndertakingscore:ListedExchangeTraded2024-01-222025-01-3115432020core:ListedExchangeTraded2024-01-222025-01-3115432020dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-01-222025-01-3115432020core:UnlistedNon-exchangeTraded2024-01-222025-01-3115432020core:NetGoodwill2026-01-3115432020core:IntangibleAssetsOtherThanGoodwill2026-01-3115432020core:LandBuildings2026-01-3115432020core:PlantMachinery2026-01-3115432020core:Vehicles2026-01-3115432020core:FurnitureFittings2026-01-3115432020core:OfficeEquipment2026-01-3115432020core:AfterOneYear2026-01-3115432020core:WithinOneYear2026-01-3115432020core:ListedExchangeTraded2026-01-3115432020core:UnlistedNon-exchangeTraded2026-01-3115432020core:ShareCapital2026-01-3115432020core:SharePremium2026-01-3115432020core:RevaluationReserve2026-01-3115432020core:OtherReservesSubtotal2026-01-3115432020core:RetainedEarningsAccumulatedLosses2026-01-3115432020core:NetGoodwill2025-01-3115432020core:IntangibleAssetsOtherThanGoodwill2025-01-3115432020core:LandBuildings2025-01-3115432020core:PlantMachinery2025-01-3115432020core:Vehicles2025-01-3115432020core:FurnitureFittings2025-01-3115432020core:OfficeEquipment2025-01-3115432020core:AfterOneYear2025-01-3115432020core:WithinOneYear2025-01-3115432020core:ListedExchangeTraded2025-01-3115432020core:UnlistedNon-exchangeTraded2025-01-3115432020core:ShareCapital2025-01-3115432020core:SharePremium2025-01-3115432020core:RevaluationReserve2025-01-3115432020core:OtherReservesSubtotal2025-01-3115432020core:RetainedEarningsAccumulatedLosses2025-01-3115432020core:NetGoodwill2024-01-2115432020core:IntangibleAssetsOtherThanGoodwill2024-01-2115432020core:LandBuildings2024-01-2115432020core:PlantMachinery2024-01-2115432020core:Vehicles2024-01-2115432020core:FurnitureFittings2024-01-2115432020core:OfficeEquipment2024-01-2115432020core:AfterOneYear2024-01-2115432020core:WithinOneYear2024-01-2115432020core:ListedExchangeTraded2024-01-2115432020core:UnlistedNon-exchangeTraded2024-01-2115432020core:ShareCapital2024-01-2115432020core:SharePremium2024-01-2115432020core:RevaluationReserve2024-01-2115432020core:OtherReservesSubtotal2024-01-2115432020core:RetainedEarningsAccumulatedLosses2024-01-2115432020core:AfterOneYear2025-02-012026-01-3115432020core:WithinOneYear2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:CostValuation2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-02-012026-01-3115432020core:Non-currentFinancialInstrumentscore:CostValuation2026-01-3115432020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-01-3115432020core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3115432020core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3115432020core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3115432020bus:Director12025-02-012026-01-3115432020bus:Director22025-02-012026-01-3115432020bus:Director32025-02-012026-01-3115432020bus:Director42025-02-012026-01-3115432020core:FurnitureFittingsToolsEquipment2025-01-3115432020core:FurnitureFittingsToolsEquipment2025-02-012026-01-3115432020core:FurnitureFittingsToolsEquipment2026-01-31

U-PLOID BIOTECHNOLOGIES LTD

Registered Number
15432020
(England and Wales)

Unaudited Financial Statements for the Year ended
31 January 2026

U-PLOID BIOTECHNOLOGIES LTD
Company Information
for the year from 1 February 2025 to 31 January 2026

Directors

Dr. Jordan Abdi
Dr. Jeremy James Anthony Buzzard
Dr. Chloe Amelia Charalambous
Dr. Alexandre Webster

Registered Address

Building 696, Innovation Building, Bioescalator Old Road Campus, Roosevelt Drive
Headington
Oxford
OX3 7FZ

Registered Number

15432020 (England and Wales)
U-PLOID BIOTECHNOLOGIES LTD
Balance Sheet as at
31 January 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Tangible assets3116,230103,511
116,230103,511
Current assets
Debtors432,76968,659
Cash at bank and on hand585,274702,113
618,043770,772
Creditors amounts falling due within one year5(18,009)(26,997)
Net current assets (liabilities)600,034743,775
Total assets less current liabilities716,264847,286
Net assets716,264847,286
Capital and reserves
Called up share capital33
Share premium116,629-
Other reserves1,806,8931,184,887
Profit and loss account(1,207,261)(337,604)
Shareholders' funds716,264847,286
The financial statements were approved and authorised for issue by the Board of Directors on 28 April 2026, and are signed on its behalf by:
Dr. Jordan Abdi
Director
Registered Company No. 15432020
U-PLOID BIOTECHNOLOGIES LTD
Notes to the Financial Statements
for the year ended 31 January 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Defined contribution pension plan
The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Research and development
All research costs are expensed. Costs related to the development of products are capitalised when they meet the criteria stated in FRS 102, Section 18 Intangible assets other than Goodwill. All other development expenditure is recognised as an expense in the period in which it is incurred.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Plant and machinery5
Fixtures and fittings4
Office Equipment3
2.Average number of employees

20262025
Average number of employees during the year63
3.Tangible fixed assets

Plant & machinery

Fixtures & fittings

Office Equipment

Total

££££
Cost or valuation
At 01 February 2594,99413,606801109,401
Additions39,3183,996-43,314
At 31 January 26134,31217,602801152,715
Depreciation and impairment
At 01 February 254,6081,198845,890
Charge for year26,3134,07420830,595
At 31 January 2630,9215,27229236,485
Net book value
At 31 January 26103,39112,330509116,230
At 31 January 2590,38612,408717103,511
4.Debtors: amounts due within one year

2026

2025

££
Amounts owed by group undertakings4,400-
Other debtors27,57667,852
Prepayments and accrued income793807
Total32,76968,659
5.Creditors: amounts due within one year

2026

2025

££
Trade creditors / trade payables8451,950
Taxation and social security15,21923,206
Other creditors1,9451,841
Total18,00926,997
6.Contingent liabilities
There were no financial guarantees or commitments, either ongoing or entered into during the period.
7.Directors advances, credits and guarantees
There were no advances, credits and guarantees granted to the directors during the period.
8.Off-balance sheet arrangements
The company had no off-balance sheet arrangements at year-end or at any stage during the period.
9.Further information regarding the company's financial position
In preparing the annual accounts the directors confirm that they believe the company can continue as a going concern for at least the next 12 months from the date of these accounts. The Directors have confirmed their intention to support the continued operation of the business.